Hyperspectral Imaging to Assess and Predict Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

256 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-03-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to test a prototype imaging instrument that relies on Medical HyperSpectral Imaging (MHSI) technology for the assessment and prediction of diabetic foot ulceration and wound healing. The imaging system utilizes the biomarkers of oxyhemoglobin (oxyHb) and deoxyhemoglobin (deoxyHb), in the upper layers of skin on the foot as: a metric for assessing wound healing, a reflection of microvascular disease, and determining tissue at risk for forming new ulcers. MHSI results will also be compare with ABI and TcPO2 measurements.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Wound Assessment Using Spectral Imaging US

NCT05415683

Diabetes Diabetic Foot Diabetic Foot Ulcer

COMPLETED

Hyperbaric Oxygen Therapy and Angiogenesis in Diabetic Patients With Foot Ulcers

NCT00475202

Diabetic Foot Ulcers Hyperbaric Therapy Angiogenesis

UNKNOWN

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

NCT06104969

Diabetic Foot Ulcer Diabetic Foot Diabetes

RECRUITING

Remote Temperature and Visual Monitoring To Help Manage Diabetic Foot Ulcers

NCT06782386

Diabetic Foot Ulcer (DFU)

ACTIVE_NOT_RECRUITING NA

C-myc Biomarker Study for Diabetic Foot Ulcers

NCT04591691

Diabetes Diabetic Foot Diabetic Foot Ulcer +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ULCER HEALING STUDY: This is a study comparing measurements from a cohort of 66 diabetic subjects (30 Type 1 and 36 Type 2) with at least one foot ulcer. The study will take place at three medical centers. Each center will enroll 22 subjects (10 Type 1 and 12 Type 2). Subjects will be required to participate in eleven (11) clinic visits over a 6 month period. The first visit will last approximately three hours and each of the other visits will last about two hours. The eleven visits will be scheduled as follows in the Table to the right.

At the initial visit the subject will give informed consent and a full medical history, and will schedule the dates of the remaining visits for the study. The subject recruiter will contact each subject one week prior to each subsequent visit to either confirm the subject's attendance or to re-schedule the visit.

NEW ULCER PREDICTION STUDY: This is a study comparing measurements of 210 "high risk" diabetic subjects (90 Type 1 and 120 Type 2) over an 18-24 month period. The study will take place at three medical centers. Each center will enroll 70 subjects (30 Type 1 and 40 Type 2). Subjects will all be required to participate in nine (9) clinic visits. The nine visits will be scheduled as follows in the Table to the right.

The first visit will last approximately three hours and each of the other visits will last about 2 hours. At the initial visit the subject will give informed consent and a full medical history, and will schedule the dates of the visits for the rest of the study. The subject recruiter will contact each subject one week prior to each subsequent visit to either confirm the subject's attendance or to re-schedule the visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with Type 1 diabetes (defined as diabetes beginning before age 35, requiring insulin, and diagnosed with diabetes for more than six months) or Type 2 diabetes.
* Presence of at least one foot ulcer

* Subjects with Type 1 diabetes (defined as diabetes beginning before age 35, requiring insulin, and diagnosed with diabetes for more than six months) or Type 2 diabetes.
* Subject without foot ulcers but at "high risk" for foot ulceration. In order to define "high risk" for this study, we are using the International Working Group standards:

1. Advanced neuropathy, defined by loss of protective sensation in the foot with a vibrational perception threshold (VPT) over 25mHz or inability to detect Semmes Weinstein 5.07 (10g) monofilament
2. Presence of significant deformity
3. Peripheral vascular disease with ankle brachial index \< 0.7
4. History of previous ulceration or presence of a foot ulcer
5. At least one foot that is ulcer free at the time of enrollment

Exclusion Criteria

* Peripheral arterial occlusive disease (PAD) that is severe enough to require surgical bypass operation.
* Cardiovascular disease as demonstrated in only these instances: congestive heart failure that leads to severe edema at the lower extremity, stroke or transient ischemic attack with residual nerve dysfunction.
* Uncontrolled hypertension: SBP\>190 mmHg or DBP \> 110 mmHg
* End stage renal disease (subjects on renal dialysis or kidney transplantation)
* Any other serious chronic disease that can affect wound healing
* Subjects currently on any of the following medications: Glucocorticoids, Antineoplastics
* Females if lactating or pregnant or, if of childbearing potential, unwilling to use standard birth control. All females of childbearing potential will undergo a pregnancy test during each visit.

NEW ULCER PREDICTION STUDY:

* Peripheral arterial occlusive disease (PAD) that is severe enough to require surgical bypass operation.
* Cardiovascular disease as demonstrated in only these instances: congestive heart failure that leads to severe edema at the lower extremity, stroke or transient ischemic attack with residual nerve dysfunction.
* Uncontrolled hypertension: SBP \> 190 mmHg or DBP \> 110 mmHg
* End stage renal disease (subjects on renal dialysis or kidney transplantation)
* Any other serious chronic disease that can affect wound healing
* Subjects on any of the following medications: Glucocorticoids and Antineoplastic agents
* Females if lactating or pregnant or, if of childbearing potential, unwilling to use standard birth control. All females of childbearing potential will undergo a pregnancy test during each visit.

Minimum Eligible Age

21 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No